We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Truist raised the firm’s price target on Elevance Health (ELV) to $510 from $480 and keeps a Buy rating on the shares as part of a broader ...

Indianapolis-based health Elevance Health’s board is recommending its investors reject a shareholder proposal that asks the ...

Mizuho raised the firm’s price target on Elevance Health (ELV) to $505 from $455 and keeps an Outperform rating on the shares. The firm ...

Fintel reports that on April 9, 2025, Guggenheim initiated coverage of Elevance Health (NYSE:ELV) with a Buy recommendation.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $477.08, along with a high estimate of $512.00 and a low estimate of $405.40. Marking an ...

Elevance Health (NYSE:ELV) is one of America's largest health insurers, serving approximately 47 million medical members through its network-based managed care plans. Larger companies benefit from ...

Elevance Health’s rally reflected growing investor confidence in its long-term strategy. Improving margins and operational efficiencies in Medicaid and Medicare Advantage plans bodes well.

Elevance Health ... operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members ...

In its fourth quarter 2024 investor letter, Hotchkis & Wiley Large Cap Fundamental Value Fund emphasized stocks such as Elevance Health, Inc. (NYSE:ELV). Elevance Health, Inc. (NYSE:ELV) is a health ...

Elevance Health (NYSE ... operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members ...

Elevance Health remains a buy with its strong fundamentals. An added bonus is its defensive nature during the tariff wars. Regulatory changes under Trump's administration and AI integration are ...